drugset
drugset / Trial / NCT07486895

Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects

NCT07486895 ↗

Phase 1 Completed 44 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to demonstrate dose strength equivalence of 2 × 164.4 milligrams (mg) centanafadine (CTN) once daily (QD) extended-release (XR) capsules to a 1 × 328.8 mg centanafadine QD XR capsule in healthy adult participants.

Timeline

Start
2023-03-08
Primary completion
2023-05-18
Completion
2023-05-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Centanafadine Small molecule 164.4 mg Oral
Subject Centanafadine Small molecule 328.8 mg Oral

Indications

No indication recorded.